about
Risk of acute myocardial infarction after transurethral resection of prostate in elderlyIdentification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitorCrystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally Designed InhibitorStructure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.GRK2 compromises cardiomyocyte mitochondrial function by diminishing fatty acid-mediated oxygen consumption and increasing superoxide levelsChronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases.Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart FailureGenetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure.GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility.Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.β-adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer's disease: a new paradigm for prognosis and therapy?Molecular aspects of the cardioprotective effect of exercise in the elderly.Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapyβ1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapyTargeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade.GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases.Impact of aging on cardiac sympathetic innervation measured by 123I-mIBG imaging in patients with systolic heart failure.Increased Epicardial Adipose Tissue Volume Correlates With Cardiac Sympathetic Denervation in Patients With Heart Failure.Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System.Impact of diabetes mellitus on lymphocyte GRK2 protein levels in patients with heart failure.Changes of plasma norepinephrine and serum N-terminal pro-brain natriuretic peptide after exercise training predict survival in patients with heart failure.EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy.GRK2 as a therapeutic target for heart failure.β Adrenergic Receptor Kinase C-Terminal Peptide Gene-Therapy Improves β2-Adrenergic Receptor-Dependent Neoangiogenesis after Hindlimb Ischemia.Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.Structural Determinants Influencing the Potency and Selectivity of Indazole-Paroxetine Hybrid G Protein-Coupled Receptor Kinase 2 Inhibitors.Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation.Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure.β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling.Burning Redoxstats in the Brainstem: Lack of Nrf2 and the Rise of Hypertension.Induction of mitogen-activated protein kinases is proportional to the amount of pressure overload.Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and PathophysiologyNovel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia familiesEating Away at Heart FailurePredisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivityGRK2 Regulates α2-Adrenergic Receptor-Dependent Catecholamine Release in Human Adrenal Chromaffin Cells
P50
Q26859700-D08D65A5-09C8-4B82-B9F7-75ABE81D6D38Q35360619-0D975594-C9DC-41A7-B00F-184B55E0C841Q35978165-CAF25814-3CE5-40DE-A33D-73E97D575E01Q35981205-16CDCBA3-826D-444D-AF44-15440F0A42D7Q36316194-884BB313-3641-4F00-8E32-3DADCA5493F9Q36399800-C8916415-90E1-40C2-A0DC-1002078C4DFFQ36629698-AA25F444-C708-4C85-AB5D-C8C0B75D660CQ36651023-FC2721ED-CB76-4F58-A95C-05DCFD7B4F1CQ36757784-921ECC0D-85B2-459E-80E5-6EA22429CF96Q36974257-EF42C4C4-FD9A-43F7-8E8E-6090AA537393Q37356016-763C5EFE-973B-4217-B0AE-7461EE4481F6Q37470858-0D8F7BFD-37D9-459F-8739-6C33CF042182Q38064688-AD2D129C-E651-4B3F-BAC8-20FB11022FCBQ38129354-992E480D-0313-41DD-99AC-D5BB1B11CE5EQ38153376-44041CE0-2E39-4C39-A141-19B0A1AFF599Q38266154-885CEB4F-C844-4F2E-9406-2F6D82F409C6Q38974127-E9FA1A0E-5A74-4840-98C4-89D1DF48AD08Q39080324-144AEF76-CABD-4F22-84A7-5663AFC2E6AAQ39403789-9EA127AA-CDBF-4349-9785-07C0E58D40EFQ39692006-84A44E19-7D09-4781-B055-FC5A7E4487DCQ39959976-D70F427F-7386-422F-9E3D-247E0380E117Q41531207-0226061C-5EB2-4EEB-A4D9-EA5705CF78E0Q41643288-738D8C9A-E024-4D96-83AD-D662A473B4C0Q44762347-F372700E-01EA-4500-8ACF-2A7011C3E218Q45197667-48128048-0A5D-4808-B877-B969EF7A8CE4Q45874891-37271F00-117A-4432-9686-2DC33691E31CQ45880995-6E6D61EE-F4A4-44AF-AD47-347399AFAC42Q46169082-B56539A4-B98B-4A40-8904-8E023A0E7439Q47603118-FF8F9235-86DD-40CE-952C-8BED8662EAC0Q48001415-820E36DE-2A61-4E50-A22D-DA91F3C6EA8EQ50978052-E28675B1-D0BB-45B8-8C18-9FADCFAA6BC5Q51831879-0CB21624-790B-4DCE-8182-36D6B7DB7553Q52096695-503176FB-3AE7-4207-BB14-00C96ED3F063Q53361030-8661BF95-962E-4F6C-856E-946F1EEDEEE8Q57493008-9796CC2F-7B28-4363-B86E-5C2CD567DA16Q58052145-B5926AF7-9951-4219-9235-50F7E3CB67BEQ86883795-70F2FF28-A5C2-4F36-802B-2B16C605DE69Q88956910-35044D94-4B6E-4E3D-948B-AE08FC74B94BQ89548525-329F7F75-3046-48BA-8BA0-6419C038BD7D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandro Cannavo
@ast
Alessandro Cannavo
@en
Alessandro Cannavo
@es
Alessandro Cannavo
@nl
type
label
Alessandro Cannavo
@ast
Alessandro Cannavo
@en
Alessandro Cannavo
@es
Alessandro Cannavo
@nl
prefLabel
Alessandro Cannavo
@ast
Alessandro Cannavo
@en
Alessandro Cannavo
@es
Alessandro Cannavo
@nl
P1053
K-7380-2016
P106
P1153
56491188600
P21
P2798
P31
P3829
P496
0000-0001-8948-5961